BIO-RAD LABORATORIES, INC.

Listed Company

BIO-BCIK 0000012208NYSELarge AcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$759.90M

Total Assets

$10.58B

Equity

$7.45B

Shares Out

27.67M

Op. Cash Flow

$532.20M

Business

Bio-Rad Laboratories, Inc. develops, manufactures and distributes life science research and clinical diagnostics products worldwide. It offers instruments, systems, reagents, consumables, test kits, informatics and quality‑control products used to separate, identify, analyze and purify biological and chemical materials. The company operates two segments: Life Science, serving research, biopharma, manufacturing and education; and Clinical Diagnostics, providing in‑vitro diagnostic systems, reagents and software for clinical laboratories. Bio-Rad sells through direct sales subsidiaries and through distributors, agents and resellers across the Americas, Europe, Middle East, Africa and Asia‑Pacific.

Summary from filing dated 2025-02-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	2,583	2,567	2,671	2,802	2,923
Cost of goods sold	1,243	1,188	1,244	1,235	1,284
Gross profit	1,340	1,379	1,427	1,567	1,638
Selling, general and administrative expense	844	814	842	828	877
Research and development expense	276	296	247	257	261
Impairment of purchased intangibles and related items, net	173	0	0	—	—
Income from operations	47	269	338	483	500
Interest expense	49	49	49	38	2
Foreign currency exchange gains, net	−7	−4	−7	−200,000	3
(Gains) losses from change in fair market value of equity securities and loan receivable	−900	2,657	1,252	5,194	−4,926
Other income, net	−90	−90	−107	−45	−27
Net income (loss) before income taxes	996	−2,343	−850	−4,704	5,449
(Provision for) benefit from income taxes	−236	498	213	1,077	−1,195
Net income (loss)	760	−1,844	−637	−3,628	4,254
Net income (loss) per basic share (in dollars per share)	27.87	−65.36	−21.82	−121.79	142.61
Weighted average common shares - basic (in shares)	27	28	29	30	30
Net income (loss) per diluted share (in dollars per share)	27.85	−65.36	−21.82	−121.79	140.83
Weighted average common shares - diluted (in shares)	27	28	29	30	30

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	530	488	404	434	471
Short-term investments	1,011	1,176	1,203	1,356	399
Restricted investments	461	453	489	495	424
Inventory	741	760	781	719	572
Prepaid expenses	137	123	140	124	109
Other current assets	28	31	26	24	10
Total current assets	2,906	3,030	3,048	3,158	1,990
Property, plant and equipment, net	540	528	529	499	512
Operating lease right-of-use assets	170	161	195	181	205
Goodwill, net	580	411	414	407	347
Purchased intangibles, net	174	294	321	332	254
Other investments	6,104	4,839	7,698	8,831	14,387
Other assets	103	102	95	95	104
Total assets	10,577	9,364	12,299	13,502	17,799
Accounts payable	129	122	145	135	142
Accrued payroll and employee benefits	172	124	140	195	277
Current maturities of long-term debt and notes payable	1	1	500,000	465,000	489,000
Income and other taxes payable	37	31	36	32	10
Current operating lease liabilities	36	42	40	36	36
Other current liabilities	142	147	162	170	128
Total current liabilities	517	468	523	569	681
Long-term debt, net of current maturities	1,202	1,200	—	—	—
Deferred income taxes	1,059	818	1,476	1,770	3,065
Operating lease liabilities	146	131	166	154	176
Other long-term liabilities	199	177	195	196	182
Total liabilities	3,123	2,795	3,558	3,886	4,114
Commitments and contingent liabilities	—	—	—	—	—
Preferred stock	0	0	0	0	0
Additional paid-in capital	476	463	449	447	442
Class A treasury stock at cost, 3,275,476 shares at 2025 and 2,254,728 shares at 2024	−1,010	−772	−633	−264	—
Retained earnings	8,176	7,416	9,261	9,898	13,525
Accumulated other comprehensive loss	−189	−538	−336	−467	−176
Total stockholders equity	7,454	6,569	8,741	9,615	13,685
Total liabilities and stockholders equity	10,577	9,364	12,299	13,502	17,799

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash received from customers	2,656	2,553	2,684	2,699	2,886
Cash paid to suppliers and employees	−2,059	−2,058	−2,241	−2,408	−2,128
Interest paid, net	−47	−47	−48	−24	−2
Income tax payments, net	−62	−99	−130	−158	−135
Dividend proceeds and miscellaneous receipts, net	81	86	100	68	35
(Payments for) proceeds from forward foreign exchange contracts, net	−38	20	8	18	13
Net cash provided by operating activities	532	455	375	194	670
Payments for purchases of property, plant and equipment	−158	−166	−157	−113	−134
Proceeds from dispositions of property, plant and equipment	100,000	100,000	200,000	200,000	52,000
Proceeds from divestiture of a division	0	0	3	1	0
Payments for business acquisitions, net of cash received	−219	0	0	−101	−126
Payments for acquired in-process research and development	0	−23	0	0	—
Payments for purchases of marketable securities and investments	−669	−1,277	−689	−2,060	−852
Proceeds from sales of marketable securities and investments	794	1,106	502	708	426
Proceeds from maturities of marketable securities and investments	62	199	361	358	341
Net cash (used in) provided by investing activities	−190	−160	20	−1,208	−797
Payments on long-term debt	−500,000	−400,000	−500,000	−500,000	−3
Payments for debt issuance costs	0	−600,000	0	0	0
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options	16	19	19	18	21
Tax payments from net share settlement	−3	−3	−15	−14	−22
Payments for purchases of treasury stock	−296	−204	−429	−216	−50
Payments of contingent consideration	0	−30	0	0	−561,000
Net cash used in financing activities	−283	−219	−426	974	−55
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	−17	9	400,000	3	−13
Net increase (decrease) in cash, cash equivalents and restricted cash	42	85	−30	−37	−196

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro